HR Execs on the Move

ICON Plc

www.iconplc.com

 
ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. We specialise in the strategic development, management and analysis of programs that support Clinical Development - from compound selection to Phase I-IV clinical studies.    In a highly fragmented industry, we are one of a small group of organisations with the capability and expertise to conduct clinical trials and development projects on either a local or global basis.    We have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated “full service” solution. We are also an 'end-to-end' Pharmacovigilance ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.iconplc.com
  • 7740 Milestone Parkway Suite 150
    Hanover, MD USA 21076
  • Phone: 410.696.3000

Executives

Name Title Contact Details
Chris Caldwell
 Vice President, Global Sales Support Profile
Prashanth Urs
 Associate IT Product Director Profile
Charles Rapier
 Sr. Director IT, R&D Solutions Profile
Lincoln Bynum
 VP, Clinical R&D Profile
Dan Johnson
 Vice President, Executive Talent Profile

Similar Companies

Aeglea

With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD.

AmbryX Biotechnology

AmbryX Biotechnology is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synspira

Synspira Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to significantly improving the lives of people with cystic fibrosis (CF) and other rare diseases.

Virsys

Virsys is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Regen BioPharma

The focus of Regen BioPharma, Inc. is to developing translational medicine platforms for the rapid commercialization of stem cell therapies and to advance intellectual property licensed from entities, institutions and universities that show promise towards fulfilling the purpose of increased quality of life. Regen BioPharma has reviewed more than 20,000 US issued patents covering stem cell related subject matter, created a shortlist of 30 promising technologies for rapid commercialization, and currently is in negotiations to license several of these. The Regen BioPharma business model is to take multiple stem cell therapeutics to and through the human "safety and signal of efficacy" stage (Phase I/II clinical trials), followed by exit. Having assembled a core infrastructure specialized in obtaining regulatory approval and executing clinical trials in cell therapy, we aim to act as a "superincubator" that within 1-2 years grows technologies from laboratory to an asset ready for spin-off or sale.